Full analysis set  
(n = 43)  
- Analyzed for safety (n = 43)  
- Analyzed for laboratory results (n = 40)

Modified intent-to-treat population (n = 42)  
- Excluded from analysis (n = 1)  
  - Did not have a confirmed documented diagnosis of candidemia (n = 1)

Per protocol population (n = 34)  
- Excluded from analysis (n = 11)  
  - Did not have a confirmed documented diagnosis of candidemia (n = 1)  
  - Inclusion/exclusion criteria violation (n = 2)  
  - Did not receive at least 5 days of i.v. anidulafungin (n = 4)  
  - Study drug compliance <75% or >120%, or other study drug-related issues (n = 4)

Allocation 
(n = 43)  
- Received i.v. anidulafungin (n = 43)  
- Received oral voriconazole (n = 14)

Discontinuations (n = 26)  
- Discontinued during active treatment (n = 13)  
  - Patient died (n = 8)  
  - Adverse events (n = 3)  
  - Lack of efficacy (n = 2)  
- Discontinued during follow-up (n = 13)  
  - Patient died (n = 2)  
  - Lost to follow-up (n = 6)  
  - Subject no longer willing to participate (n = 4)  
  - Other (n = 1)  
Completed study (n = 17)

Analysis  

Follow-up  
(n = 46)  
- Excluded (n = 3)

Allocation  

Enrollment  
(n = 46)  
- Excluded (n = 3)

Assessed for eligibility  
(n = 46)

Per protocol population (n = 34)
- Excluded from analysis (n = 11)  
  - Did not have a confirmed documented diagnosis of candidemia (n = 1)  
  - Inclusion/exclusion criteria violation (n = 2)  
  - Did not receive at least 5 days of i.v. anidulafungin (n = 4)  
  - Study drug compliance <75% or >120%, or other study drug-related issues (n = 4)